| Recruiting | Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) fo NCT06498648 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma NCT06968988 | Washington University School of Medicine | Phase 1 |
| Recruiting | T Cell Membrane-Anchored Tumor-Targeted IL12 -Modified TIL Cell Therapy (attIL12-TIL) for Advanced/Metastatic NCT06474676 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma NCT06797999 | Adcendo ApS | Phase 1 / Phase 2 |
| Active Not Recruiting | Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advan NCT05836571 | National Cancer Institute LAO | Phase 2 |
| Withdrawn | Gemcitabine With Ascorbate Including Adolescents NCT04877587 | David Dickens | EARLY_Phase 1 |
| Active Not Recruiting | HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas NCT05180695 | Centre Leon Berard | Phase 1 / Phase 2 |
| Recruiting | Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma NCT04874311 | Institut Bergonié | Phase 2 |
| Terminated | A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma NCT05100628 | Noxopharm Limited | Phase 1 |
| Active Not Recruiting | Lurbinectedin + Doxorubicin In Leiomyosarcoma NCT05099666 | Massachusetts General Hospital | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide NCT05075993 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma NCT04757337 | UNICANCER | Phase 3 |
| Active Not Recruiting | Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma NCT04551430 | Washington University School of Medicine | Phase 2 |
| Recruiting | Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases NCT03965234 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Recruiting | Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas NCT04028063 | University of Colorado, Denver | Phase 2 |
| Active Not Recruiting | Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tis NCT04200443 | City of Hope Medical Center | Phase 2 |
| Terminated | Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas NCT03670069 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Phase II Study of Regorafenib as Maintenance Therapy NCT03793361 | Centre Oscar Lambret | Phase 2 |
| Terminated | Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcoma NCT03660930 | University of Washington | Phase 1 / Phase 2 |
| Withdrawn | Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma NCT03397186 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma NCT03138161 | Sarcoma Oncology Research Center, LLC | Phase 1 / Phase 2 |
| Completed | Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot B NCT03009201 | OHSU Knight Cancer Institute | Phase 1 |
| Completed | Geriatric Assessmen of Elderly "Unsuited" Patients Receiving Trabectedin in First Line Treatment For Advanced NCT03022448 | GWT-TUD GmbH | — |
| Completed | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Su NCT02500797 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation NCT01574716 | Morphotek | Phase 2 |
| Completed | Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma NCT01514188 | ImmunityBio, Inc. | Phase 2 |